Wake Research Associates Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Raleigh NC United States (1984)

Organization Overview

First Clinical Trial
2007
NCT00419263
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Carolina Phase I Research, LLC | Wake Research Associates, LLC | Wake Research Associates, LLM

Active Ingredients

Drugs in Phase 4 Trials (1)

prednisone (meticorten) (1 trial)

Drugs in Phase 3 Trials (1)

lubiprostone (amitiza) (2 trials)

Drugs in Phase 2 Trials (5)

bupropion (wellbutrin) (1 trial)

Dapansutrile (1 trial)

nb-001 (1 trial)

peramivir (rapivab) (1 trial)

zonisamide (Zonegran) (1 trial)

Drugs in Phase 1 Trials (5)

acetylcysteine (mucomyst) (1 trial)

ec-18 (1 trial)

medi7510 (1 trial)

sufentanil (1 trial)

sumatriptan (zecuity) (1 trial)

Drugs in Other Trials (1)

pravastatin (pravachol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Constipation (Phase 3)

Deafness (Phase 1)

Dermatitis (Phase 4)

Dermatitis, Atopic (Phase 4)

Hearing Loss (Phase 1)

Hearing Loss, Noise-Induced (Phase 1)

Hearing Loss, Sensorineural (Phase 1)

Herpes Labialis (Phase 2)

Influenza, Human (Phase 2)

Irritable Bowel Syndrome (Phase 2)

Migraine Disorders (Phase 1)

Neutropenia (Phase 1)

Obesity (Phase 2)

Osteoarthritis (Phase 2)

Osteoarthritis, Knee (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 12
  • # of Trial APIs: 13